SET is overexpressed in several hematological malignancies such as undifferentiated leukemia [1], T-ALL [59,74,80], BCR-ABL positive CML and B-ALL [7], B-ALL [10], B-CLL and non-Hodgkin’s lymphoma (NHL) [11], AML [13,81–83] and solid tumors, including Wilm’s tumors [84], lung tumor [57,85], metastatic colon rectal cancer [51,86,87], breast cancer [14,88,89], gastic cancer [90,91], pancreatic cancer [92], head and neck squamous carcinoma [70], endometrial cancer [51] and ovarian cancer [93] (Figure 3). Here, SET is linked to non-Hodgkin lymphoma.